Tetracycline inhibits bacterial protein synthesis and inhibits bacterial protein degradation in a variety of bacterial species, including both Gram-positive and Gram-negative bacteria. This inhibition of protein synthesis is thought to be due to interference with the bacterial protein-metabolizing enzymes, including the cytoplasmic membrane-bound proteins, the cytoplasmic membrane proteins and the endoplasmic reticulum. Tetracycline has been shown to inhibit bacterial protein synthesis in both Gram-positive and Gram-negative bacteria.

The inhibitory effect of Tetracycline on bacterial protein synthesis is not a direct result of its inhibition of protein degradation. The inhibition of protein synthesis by Tetracycline is also an indirect result of interference with the bacterial protein-metabolizing enzymes, including the cytoplasmic membrane-bound proteins, the cytoplasmic membrane proteins and the endoplasmic reticulum. One such protein degradation pathway is the endoplasmic reticulum. When the endoplasmic reticulum is activated, the bacteria can release the cytoplasmic membrane proteins, the cytoplasmic membrane proteins and the cytoplasmic membrane proteins, which then accumulate in the cytosol. The cytoplasmic membrane proteins then are processed and the bacterial protein synthesis is inhibited.

To test this hypothesis, the investigators used a model system to study the effect of tetracycline on the activity of bacterial protein synthesis in gram-negative and gram-positive bacteria. In the model system, a synthetic tetracycline derivative, 1,3,6-tetramazofurium chloride, was used. The model system was tested for the presence of cytoplasmic membrane proteins in the bacterial cell. In gram-positive bacteria, the antibiotic caused a significant reduction in the activity of the bacterial protein synthesis in the bacterial cell, resulting in a significant reduction in bacterial protein production. The effect of tetracycline on the bacterial protein synthesis in gram-negative and gram-positive bacteria was blocked using a tetracycline derivative, 3-(4,5-dimethylthio)-2,5-dihydro-1,3,6-tetramazofurium chloride. The inhibitory effect of tetracycline on the bacterial protein synthesis in gram-negative and gram-positive bacteria was blocked using the tetracycline derivative.

To determine the effect of tetracycline on bacterial protein synthesis in gram-negative and gram-positive bacteria, the following compounds were used: 3-(4,5-dimethylthio)-2,5-dihydro-1,3,6-tetramazofurium chloride, 1,3,6-tetramazofurium chloride, and 3-(4,5-dimethylthio)-2,5-dihydro-1,3,6-tetramazofurium chloride.

Tetracycline has been shown to inhibit the growth and survival of some Gram-positive bacteria. For example, the drug inhibited the growth and survival ofStaphylococcus aureus,Streptococcus pyogenesKlebsiella pneumoniae, andStreptococcus pneumoniaein an in vitro experiment using the inducible expression system. Tetracycline also caused the growth and survival ofE. coliandstrains in the in vivo experiment. In the in vitro experiment, tetracycline caused the growth and survival ofstrains.

The investigators used the Tetracycline-based system to demonstrate that tetracycline is an effective antibiotic that inhibits bacterial protein synthesis in both Gram-positive and Gram-negative bacteria. To test this hypothesis, the investigators examined the effects of tetracycline on the activity of the bacterial protein synthesis in gram-positive and gram-negative bacteria.

The study showed that tetracycline inhibited the growth and survival ofstrains in an in vitro experiment.

Side Effects:Doxycycline side effects in dogs, cats and horses include stomach upset, vomiting, reduced appetite, and diarrhea. Giving doxycycline with food may help alleviate these GI effects. Reddening or sunburn can occur to hairless skin around nose, eyelids and ears when exposed to sunlight.Warnings:Do not use in animals allergic to doxycycline or other tetracycline drugs. Use with caution in animals with liver problems. Milk or other dairy products, calcium, oral antacids, iron, or bismuth subsalicylate must be separated from doxycycline doses by at least 2 hours. Overdoses can be very dangerous. Keep out of reach of children and animals. Always follow the dosage instructions provided by your veterinarian. If you have difficulty giving the medication, contact your veterinarian. If you miss a dose, give it as soon as you remember. If it is almost time for the next dose, skip the one you missed and go back to the regular schedule. Do not give two doses at once. This medication should only be given to the pet for whom it was prescribed.

Side Effects

Serious side effects of doxycycline include a dangerous increase in heart rate, seizures, heart attack, or breathing problems. If you experience any of the following, get emergency medical attention immediately: remembered heart attack or breathing problems, SAGE of eye problems such as pronounced field ventricular tachycard (VFR) or severe severe field heart failure, Liver or kidney disease, or jaundice (yellowing of the skin or eyes)These side effects are usually mild and non-feeling. If you experience severe or persistent side effects, it is important to immediately contact veterinary immediately. Do not give this medication to children or animals. Doxycycline also may cause an increased risk of blood clots, especially in animals with preexisting heart disease. Use caution when giving doxycycline to animals and use it at the same time each day. It is recommended that heart rhythm problems first appear within 14 days of signs of this medication, and then periodically re-appear. Doxycycline should be used with extreme care and regular monitoring to avoid potential drug interactions. It is important to continue, once every 24 hours, that the pet have heart health. monitor the pet for signs of cardiac events, such as unusual dizziness, fainting, or palpitations. Doxycycline may rarely cause angle-closure glaucoma (known as an X-ray) which, if congested, can lead to a sudden decrease in fluid levels and gastrointestinal symptoms (such as open pupils). angle-closure glaucoma can be a symptom of chlamdism because it occurs when the eye is closer to the vagina than the eye goes to. This medication should only be used to treat bacterial or parasitic infections, to treat infections that are serious, and to prevent recurrent infections. It is important to finish the full course of treatment for this medication. It is recommended that heart rhythm problems first appear 129 days after signs of tetracyclines, and thereafter may re-appear if new signs are present. Doxycycline can increase your sensitivity to touch, and you should not engage in any activity that requires you to be quiet or be aroused. It is important to continue, once every 24 hours, that heart rhythm problems first appear 129 days after signs of this medication, and thereafter re-appear once every 48 hours. If you are giving doxycycline to a pet, make sure it isqualityened before giving to human beings. See veterinary. Doxycycline can cause an increased risk of blood clots, especially in animals with low heart rhythms. Your veterinarian may be able to prescribe a different medication, depending on your circumstances. Your pet is likely to experience these side effects if you give this medication to them at the same time each day. They may need to change the dose of the medication, monitor the pet for signs of cardiac events, and if needed re-appear.

Ask your veterinarian if you are giving doxycycline to a pet for animals who have a history of cardiovascular disease or liver or kidney problems, diabetes, heart rhythm problems (, or QT prolongation, QTc prolongation, torsades de pointes, QT prolongation and right ventricle thrombophlebitis ) and.

Tetracycline HCl 500 mg USP, USP, CLOMEL, or DUTCH

by Drugs.com. Last updated ed. July 2025.This drug information is based upon multiple public health information sources with some limitations. The information provided on this Web site is not intended as a substitute for professional medical advice, medical advice provided by your health care provider, or your input as to a good starting point for your own health problems. You should not use this Web site for the wrong purpose. Do not use this Web site for the wrong purpose. If you have any questions, consult your health care provider or pharmacist.

Tetracycline HCl is a prescription drug. Generic tetracycline can be purchased without a prescription from a licensed health care professional without requiring a prescription from your doctor. The drug is available in a dosage of 500 mg and is manufactured in various forms including tablets, capsules, injection, and oral suspension. The drug is used to treat a wide range of bacterial infections, including:

• Respiratory tract infections (including sinusitis, pneumonia, bronchitis)
• Skin infections
• Dental infections
• Typhoid fever
• Anthrax (the most common type of plague)
• Post-nasal drip
• Typhoid
• Other respiratory infections (including pneumonia)

Tetracycline HCl is not approved by the FDA to treat viral infections such as herpes simplex and varicella-zoster.

The drug is also available for use in the management of chronic obstructive pulmonary disease (COPD)

Tetracycline HCl is also approved by the FDA for the treatment of typhoid fever in travelers to high altitudes (at least ), but there is some controversy over its efficacy and safety. Studies show that tetracyclines can help prevent severe infections caused byH. pyloriinfection.

While the drug is not approved by the FDA for the treatment of bacterial pneumonia, it is also available to treat bacterial sinusitis. It may be prescribed for a few more infections caused byStaphylococcus aureus, includingS. aureus. It may be used for the treatment of bacterial vaginosis (vaginitis).

The drug is available for use in the management of bacterial pneumonia in adults and children. The drug can also be used to treat the symptoms ofPneumocystis aureomyxis(PCA) in children.

Tetracycline HCl is not approved for use in children under 12 years old. Tetracycline HCl is only approved for use in children.

The drug is available to treat infections caused by susceptible gram-positive and gram-negative bacteria.

Dosage and Administration

The dosage of tetracycline HCl 500 mg USP is based on the specific infection being treated. For the treatment of bacterial pneumonia, the usual adult dose is 500 mg every 8 hours for the first 2 weeks, followed by 250 mg every 8 hours for the remainder of the treatment period. It may be increased to 500 mg every 12 hours for the first 2 weeks, followed by 250 mg every 12 hours for the remainder of the treatment period. The dosage may be adjusted based on the severity and response of the infection.

Side Effects

The following side effects have been reported with the use of tetracycline HCl 500 mg USP.

• Nausea, vomiting, and diarrhea
• Diarrhea
• Abdominal pain
• Headache
• Insomnia
• Increased urination
• Stomach upset
• Vomiting
• Weight loss
• Increased appetite
• Bloating
• Increased heart rate
• Rash
• Increased sweating
• Increased blood pressure
• Skin reactions

Serious side effects have been reported in patients receiving tetracycline HCl 500 mg USP.

Kloner M, Krasen M, Fuscinesium P, Gossen A, et al. (2012) Tet-responsive gene expression systems for the study of cellular immunity and inflammation. Nature. [published online] Available at

Mourinho G, Sousa R, Costa D, Costa A, et al. (2013) Tetracycline-responsive promoters: the first in vitro and in vivo systems to be used in cell culture. Proc Natl Acad Sci USA. [doi: 10.1073/pnas.12074912.13]

Tobacco-related gene expression systems: TAS and TGF-β. Appl Biochem Biophys Res Commun. [doi:10.1136/ajc.1020]

McMahon JE, Gossen A, Riedel A, et al. (2016) Expression and physiology of TGF-β-responsive promoters in human cells. Nat Med. [doi:10.1038/ni.2016.04]

Chen D, Shamsuddin A, Kallman E, Gossen A, et al. (2016) Effect of tetracycline on cellular immunity: a model of immunity-associated immunity. J Immunol. [doi:10.1093/JI.15-3].

Mangarese D, Visser M, Gossen A, Schoenfeld T, et al. (2013) Tetracycline-responsive promoter activity in a model of lymphocyte proliferation. [doi:10.1093/ij.15-3].

Riordan Y, Althof F, Sankar M, Kothai M, et al. (2016) Tetracycline-responsive promoters: a model for cell immunity. Nat Rev Mol Gen.

Tibbs H, McLean H, Kallman E, Schoenfeld T, et al. (2012) Tetracycline-responsive promoter activity in a model of lymphocyte proliferation. [doi:10.1073/pnas.12074912.13]

Hempen B, Althof F, Sankar M, Kallman E, et al. (2016) Tetracycline-responsive promoter activity in a model of lymphocyte proliferation.

Cernera A, Sankar M, Althof F, Kallman E, et al. (2017) Tetracycline-responsive promoters in cancer. Nat Commun. [doi:10.2147/NCT1717078]

Borovits P, Chlok J, Minkovski D, Sankar M, et al. (2009) Tetracycline-responsive promoter activity in cancer cells. [doi:10.2147/NCT1707818]

Hertzberg L, Fenton W, Schoenfeld T, Minkovski D, et al. (2004) Tetracycline-responsive promoter activity in a model of lymphocyte proliferation. Mol Biol Cell Biol. [doi:10.1128/MBL.0018-14]

Borovits P, Chlok J, Sankar M, Sankar M, et al.

Lambs P, Balsam M, Rochat K, Minkovski D, et al. (2001) Tetracycline-responsive promoter activity in a model of lymphocyte proliferation. [doi:10.1128/MBL.0018-15]

Chu Y, Yang M, Yang H, Shamsuddin A, et al.